Literature DB >> 647693

Tamoxifen retinopathy.

M I Kaiser-Kupfer, M E Lippman.   

Abstract

Tamoxifen has been used as a chemotherapeutic agent with no serious side effects noted. Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes. Three of the four patients had a significant decrease in visual acuity as the result of a retinopathy, primarily affecting the region about the macula accompanied by macular edema. In addition, three of the four patients had unusual corneal changes. These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647693

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  31 in total

Review 1.  The differential diagnosis of crystals in the retina.

Authors:  F Nadim; H Walid; J Adib
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Tamoxifen retinopathy: a rare but serious complication.

Authors:  C R Bentley; G Davies; W A Aclimandos
Journal:  BMJ       Date:  1992-02-22

3.  To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity.

Authors:  Tejaswi Bommireddy; Zia Iqbal Carrim
Journal:  BMJ Case Rep       Date:  2016-01-11

4.  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

Authors:  William J Irvin; Christine M Walko; Karen E Weck; Joseph G Ibrahim; Wing K Chiu; E Claire Dees; Susan G Moore; Oludamilola A Olajide; Mark L Graham; Sean T Canale; Rachel E Raab; Steven W Corso; Jeffrey M Peppercorn; Steven M Anderson; Kenneth J Friedman; Evan T Ogburn; Zeruesenay Desta; David A Flockhart; Howard L McLeod; James P Evans; Lisa A Carey
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

Review 5.  Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?

Authors:  M O'Brien; T J Powles
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

6.  Tamoxifen therapy conveys increased risk of developing a macular hole.

Authors:  Brendan G Cronin; Christopher K Lekich; Robert D Bourke
Journal:  Int Ophthalmol       Date:  2006-09-15       Impact factor: 2.031

7.  Update in cancer chemotherapy: general considerations and breast cancer, Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-08       Impact factor: 1.798

Review 8.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.

Authors:  J Bishop; R Murray; L Webster; P Pitt; K Stokes; A Fennessy; I Olver; G Leber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.